{"id":"recombinant-human-bnp-1-32","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Worsening renal function"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1201718","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BNP(1-32) is a shorter, biologically active fragment of B-type natriuretic peptide that binds to natriuretic peptide receptor-A (NPR-A) on vascular smooth muscle and endothelial cells. This activation triggers increased cGMP production, leading to vasodilation, reduced sodium reabsorption, and decreased sympathetic nervous system activity. The net effect is improved hemodynamics and reduced cardiac workload in heart failure patients.","oneSentence":"Recombinant human BNP(1-32) is a truncated B-type natriuretic peptide that activates natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and inhibit the renin-angiotensin-aldosterone system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:05.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute decompensated heart failure"}]},"trialDetails":[{"nctId":"NCT03397966","phase":"PHASE4","title":"Metabolic Effects of Natriuretic Peptide Hormones","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-07-01","conditions":"Obesity, Cardiovascular Physiological Phenomena, Metabolism","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["nesiritide, Natrecor"],"phase":"marketed","status":"active","brandName":"recombinant human BNP(1-32)","genericName":"recombinant human BNP(1-32)","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human BNP(1-32) is a truncated B-type natriuretic peptide that activates natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and inhibit the renin-angiotensin-aldosterone system. Used for Acute decompensated heart failure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}